Pharmaceuticals: KOL meeting on dermatology: bimekizumab and Dupixent in pole position
PharmaceuticalsKOL meeting on dermatology: bimekizumab and Dupixent in pole position
Psoriasis (I): bimekizumab seen as the best biologic
Psoriasis (II): JAK inhibitors far less potent than biologics
Atopic Dermatitis (AD): Dupixent should remain the drug of choice for many years
Other skin diseases: some significant markets to create
Conclusions by company
Since 1996, Bryan, Garnier & Co has been growing with an absolute conviction that the investment banking landscape would experience a major revolution: most of the large local generalist banking groups will disappear to the benefit of a handful of global powerhouses, and an emerging group of independent, highly specialised boutique investment banks.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.